ALUR · XBRL financial data

Allurion Technologies financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ALUR's year ends in late December)

In thousands of dollars	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	53,467	32,110	15,230
Cost of revenue	11,970	10,607	5,659
Gross profit	41,497	21,503	9,571
Research and development	27,694	17,369	7,571
General and administrative	46,024	28,399	21,353
Total operating expenses	120,575	71,701	39,728
Operating income (loss)	(79,078)	(50,198)	(30,157)
Interest expense	10,566	2,264	0
Other income (expense)	(643)	1,452	982
Income tax expense (benefit)	264	718	74
Net income (loss)	(82,817)	(7,198)	(28,755)
Earnings per share, basic USD per share	(59.38)	(3.20)	(3.81)
Earnings per share, diluted USD per share	(59.38)	(3.20)	(3.81)
Weighted average shares, basic thousands of shares	1,423	2,247	7,545
Weighted average shares, diluted thousands of shares	1,423	2,247	7,545

† Share count changed about 1/8 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ALUR's year ends in late December)

In thousands of dollars	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	38,037	15,379	5,412
Accounts receivable	18,194	7,134	3,951
Inventory	6,171	3,400	2,670
Prepaid and other current assets	2,414	1,243	759
Total current assets	64,816	27,156	12,792
Property and equipment, net	3,381	2,469	1,367
Right-of-use asset	3,010	2,079	950
Total assets	71,712	32,813	15,772
Accounts payable	10,379	6,572	3,568
Current portion of long-term debt	38,643	35,710	—
Total current liabilities	65,425	18,863	38,445
Long-term debt	—	35,710	0
Lease liability, non-current	2,306	1,344	571
Total liabilities	143,009	110,791	92,961
Accumulated deficit	(215,009)	(222,207)	(250,962)
Total stockholders' equity	(71,297)	(77,978)	(77,189)
Total liabilities and equity	71,712	32,813	15,772
Common shares outstanding (cover page) thousands of shares	47,852	5,964	14,994

† Share count changed about 1/8 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ALUR's year ends in late December)

In thousands of dollars	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(82,817)	(7,198)	(28,755)
Stock-based compensation	8,357	3,056	3,146
Net cash from operating activities	(63,982)	(42,300)	(28,946)
Purchases of property and equipment	1,606	611	—
Net cash from investing activities	(1,606)	(611)	—
Net cash from financing activities	95,986	20,208	18,970
Net change in cash	30,398	(22,703)	(9,976)

† Share count changed about 1/8 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Allurion Technologies	5,056	2,947	(3,221)	15.0M	1.6 quarters	Q1 FY26 10-QMar 31, 2026
Neuraxis	8,322	1,929	(1,030)*	12.6M	—	Q2 FY26 10-QJun 30, 2026
Positron	357	112	(1,050)*	32.8M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Dror Ortho-Design	94	not reported	(305)*	977.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Vivos Therapeutics	1,774	5,153	(3,148)*	20.1M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026
CapsoVision	not reported	3,643	(8,403)*	50.0M	—	Q2 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.